🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

842 results for “Eli” Clear

  1. BGB-A445

    Beone Medicines Ireland Limited

    Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  2. Bacteriophage Therapy

    Adaptive Biotechnologies Corp

    Osteomyelitis

    phase 2 mab terminated

    1 trial

  3. Bavencio 20 mg/mL concentrate for solution for infusion

    Disc Medicine

    locally advanced urothelial cancer.

    phase 2 small molecule active

    1 trial

  4. Behavioral Drug and Risk Counseling (BDRC)

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Risk Behaviors

    phase 2 other completed

    1 trial

  5. Benlysta 200 mg solution for injection in pre-filled syringe., Placebo of belimumab

    Pari Pharma GmbH

    Cryoglobulinemia vasculitis

    phase 2 small molecule active

    1 trial

  6. Brenipatide, Brenipatide, Brenipatide, Brenipatide, Placebo to match LY

    Eli Lilly Co.

    Asthma

    phase 2 small molecule active

    1 trial

  7. Brentuximab Vedotin in Combination with Tislelizumab

    Takeda Pharmaceuticals International AG

    NK/T Cell Lymphoma Nos

    phase 2 small molecule active

    1 trial

  8. Brief computer-delivered intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 other completed

    1 trial

  9. Budigalimab, Telisotuzumab adizutecan, Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Advanced or Metastatic Non-Squamous NSCLC

    phase 2 small molecule active

    1 trial

  10. CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coat

    Fondazione Telethon ETS

    bladder carcinoma of urothelial and non-urothelial histology

    phase 2 small molecule active

    1 trial

  11. CAPECITABINE, CAPECITABINE, TRIPTORELIN, [177Lu]-NeoB solution for infusion, LEUPRORELIN, AAA503, GOSERELIN

    Novartis Ophthalmics Europe

    Breast Cancer

    phase 2 small molecule active

    1 trial

  12. CARBOPLATIN , JNJ-42756493, JNJ-63723283, CISPLATIN , JNJ-42756493, JNJ-63723283, JNJ-42756493

    Janssen-Cilag International N.V.

    Metastatic or Locally Advanced Urothelial Cancer

    phase 2 small molecule active

    1 trial

  13. CCRT with Maintenance Tislelizumab and Metronomic Capecitabine

    Beone Medicines Ireland Limited

    Nasopharyngeal Carcinoma

    phase 2 other active

    1 trial

  14. CEFAZOLIN, CLOXACILLIN, CLAVULANIC ACID, AMOXICILLIN, AMOXICILLIN

    Pari Pharma GmbH

    acute osteomyelitis of the child

    phase 2 small molecule active

    1 trial

  15. CERE-120: Adeno-Associated Virus Delivery of Neurturin

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 mab completed

    1 trial

  16. CHOP+selinexor+5-Azacitidine

    China SXT Pharmaceuticals

    Peripheral T Cell Lymphoma

    phase 2 small molecule active

    1 trial

  17. CPK850

    Novartis Ophthalmics Europe

    Retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene

    phase 2 small molecule active

    1 trial

  18. Camrelizumab

    First Tracks Biotherapeutics

    Gastric Cancer Stage III

    phase 2 small molecule active

    1 trial

  19. Camrelizumab

    First Tracks Biotherapeutics

    Lung Cancer, Nonsmall Cell

    phase 2 small molecule active

    1 trial

  20. Camrelizumab

    First Tracks Biotherapeutics

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  21. Camrelizumab

    First Tracks Biotherapeutics

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  22. Camrelizumab

    First Tracks Biotherapeutics

    Locally Advanced or Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  23. Camrelizumab

    First Tracks Biotherapeutics

    Melanoma

    phase 2 small molecule active

    1 trial

  24. Camrelizumab

    First Tracks Biotherapeutics

    Lung Neoplasms

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources